Clinical trial · Interventional
Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes
Therapeutic and Biological Effects of Imatinib Mesylate in Primary Hypereosinophilic Syndromes
NCT00787384CI-TRIAL-00004238NILG-HES1-03completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study was performed to assess: 1) clinical activity of Imatinib in patients with HES, CEL and CIH; 2) correlation between Imatinib activity and specific disease subtype; 3) long-term outcome of HES, CEL and CIH patients treated with Imatinib; 4) safety and tolerability of Imatinib administration.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Eosinophilic Leukemia | Chronic Eosinophilic Leukemia, Not Otherwise Specified | ONTOLOGY_EXACT | 0.98 |
| Chronic Idiopathic Hypereosinophilia | — | UNRESOLVED | — |
| Hypereosinophilic Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Imatinib | Drug | Imatinib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Imatinib
- description
- Patients received oral imatinib 100 mg/d; in case of unsatisfactory response (less than complete) Imatinib could be increased by 100 mg/die on a weekly basis and up to a maximum of 400 mg/die. Imatinib was discontinued after 12 total weeks of therapy.
- interventionNames
- Drug: Imatinib
Primary outcomes (1)
- measure
- Response rate
Secondary outcomes (4)
- measure
- Safety: Adverse events and serious adverse events
- measure
- Time to response
- measure
- Diagnostic profile of Imatinib-responsive cases
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 15 Years
Show eligibility criteria text
Inclusion Criteria: * patients with a diagnosis of HES, CEL and CIH, who are either previously untreated or have been treated with corticosteroids, cytotoxic drugs, and IFN. * age \> 15 years. * signature of a written informed consent(by parents/tutors for patients aged \< 18 years). Exclusion Criteria: * patients with a diagnosis of secondary hypereosinophilia * age \< 15 years
References
Publications (1)
- RESULTIntermesoli T, Delaini F, Acerboni S, Salmoiraghi S, Spinelli O, Guerini V, Vannucchi AM, Mappa S, Rossi G, Rossi V, Di Bona E, Paratore S, Carobbio A, Rambaldi A, Barbui T, Bassan R. A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes. Br J Haematol. 2009 Dec;147(5):681-5. doi: 10.1111/j.1365-2141.2009.07893.x. Epub 2009 Sep 4. PMID 19735261